Drug Combination Details
| General Information of the Combination (ID: C64312) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | MG262 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| H22 | CVCL_H613 | Hepatocellular carcinoma of the mouse | Mus musculus | |||
| In-vivo Model | Murine hepatoma H22 cells (10 * 106) suspended in 0.2 ml of serum-free RPMI 1640 were inoculated s.c. in the left armpit of each mouse. | |||||
| Experimental
Result(s) |
The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011 Feb 28;301(2):221-8. | |||
